Pretomanid Disease Interactions

The use of pretomanid with the combination regimen of bedaquiline and linezolid has been associated with hepatic adverse reactions. It is recommended to monitor for signs and symptoms of hepatotoxicity and assess liver test at baseline, at two weeks, and then monthly while on treatment and as needed. Interrupt therapy as recommended by the manufacturer and avoid alcohol and hepatotoxic agents, especially in patients with hepatic impairment.

The use of pretomanid with the combination regimen of bedaquiline and linezolid has been associated with QT prolongation. It is recommended to obtain an ECG before starting treatment and at least 2, 12, and 24 weeks during treatment. Obtain serum potassium, calcium, and magnesium at baseline and correct if abnormal. Monitor these electrolytes if QT prolongation is detected. Exercise care when using this agent in patients with a history of Torsade de Pointes, congenital long QT syndrome, hypothyroidism, bradyarrhythmia, uncompensated heart failure, or serum calcium, magnesium, or potassium levels below the lower limits of normal. If syncope occurs, obtain an ECG to detect QT prolongation. Discontinue treatment if clinically significant ventricular arrhythmia or a corrected QT interval by Fredericia (QTcF) interval of greater than 500 milliseconds, as confirmed by repeat ECG, develops.